Brokerages expect that Gilead Sciences, Inc. (NASDAQ:GILD) will report earnings of $1.52 per share for the current quarter, Zacks Investment Research reports. Seven analysts have issued estimates for Gilead Sciences’ earnings, with estimates ranging from $1.44 to $1.60. Gilead Sciences posted earnings of $2.56 per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 40.6%. The firm is scheduled to issue its next quarterly earnings results on Wednesday, July 25th.
On average, analysts expect that Gilead Sciences will report full year earnings of $6.10 per share for the current year, with EPS estimates ranging from $5.85 to $6.38. For the next year, analysts anticipate that the company will post earnings of $6.34 per share, with EPS estimates ranging from $5.75 to $7.27. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research firms that follow Gilead Sciences.
Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, May 1st. The biopharmaceutical company reported $1.48 EPS for the quarter, missing analysts’ consensus estimates of $1.67 by ($0.19). Gilead Sciences had a net margin of 14.03% and a return on equity of 45.49%. The firm had revenue of $5.09 billion for the quarter, compared to analysts’ expectations of $5.40 billion. During the same period in the prior year, the company posted $2.23 earnings per share. Gilead Sciences’s quarterly revenue was down 21.8% compared to the same quarter last year.
GILD has been the topic of a number of research reports. BidaskClub upgraded Gilead Sciences from a “strong sell” rating to a “sell” rating in a report on Wednesday, June 6th. Zacks Investment Research upgraded Gilead Sciences from a “sell” rating to a “buy” rating and set a $85.00 target price on the stock in a report on Thursday, April 19th. Barclays dropped their target price on Gilead Sciences from $95.00 to $90.00 and set a “buy” rating on the stock in a report on Wednesday, May 2nd. Piper Jaffray Companies initiated coverage on Gilead Sciences in a report on Wednesday, May 30th. They issued a “buy” rating and a $85.00 price objective on the stock. Finally, Leerink Swann set a $72.00 price objective on Gilead Sciences and gave the stock a “market perform” rating in a report on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, ten have issued a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $88.00.
Shares of Gilead Sciences traded down $0.45, reaching $71.07, during trading hours on Tuesday, according to MarketBeat Ratings. The company’s stock had a trading volume of 6,118,885 shares, compared to its average volume of 7,177,516. The company has a market capitalization of $92.99 billion, a price-to-earnings ratio of 8.30, a P/E/G ratio of -6.22 and a beta of 1.15. Gilead Sciences has a 1-year low of $64.27 and a 1-year high of $89.54. The company has a debt-to-equity ratio of 1.32, a current ratio of 2.84 and a quick ratio of 2.75.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 28th. Shareholders of record on Friday, June 15th will be paid a dividend of $0.57 per share. The ex-dividend date is Thursday, June 14th. This represents a $2.28 annualized dividend and a yield of 3.21%. Gilead Sciences’s dividend payout ratio is currently 26.64%.
In related news, Director John C. Martin sold 50,000 shares of Gilead Sciences stock in a transaction dated Monday, April 2nd. The stock was sold at an average price of $73.14, for a total value of $3,657,000.00. Following the completion of the sale, the director now directly owns 3,067,762 shares in the company, valued at $224,376,112.68. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director John Francis Cogan sold 5,833 shares of Gilead Sciences stock in a transaction dated Friday, April 6th. The stock was sold at an average price of $74.47, for a total value of $434,383.51. Following the completion of the sale, the director now owns 58,452 shares of the company’s stock, valued at $4,352,920.44. The disclosure for this sale can be found here. Insiders have sold 179,168 shares of company stock valued at $12,789,233 over the last quarter. Corporate insiders own 1.30% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the stock. Archford Capital Strategies LLC bought a new position in shares of Gilead Sciences during the 1st quarter valued at about $106,000. Certified Advisory Corp acquired a new position in shares of Gilead Sciences during the 4th quarter worth approximately $133,000. Advisors Preferred LLC acquired a new position in shares of Gilead Sciences during the 1st quarter worth approximately $140,000. Stelac Advisory Services LLC bought a new stake in shares of Gilead Sciences during the 1st quarter valued at $141,000. Finally, Mckinley Capital Management LLC Delaware lifted its position in shares of Gilead Sciences by 67.7% during the 1st quarter. Mckinley Capital Management LLC Delaware now owns 2,130 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 860 shares during the period. Hedge funds and other institutional investors own 77.60% of the company’s stock.
About Gilead Sciences
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.